407 related articles for article (PubMed ID: 35842249)
1. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
2. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Dupilumab in Pediatric Patient With Prurigo Nodularis-Like Atopic Dermatitis.
Yiling Y; Ali K; Jiayang D; Qiu Y; Kai G; JinPeng S; Tianci X; Min C; Menghua L; Liming W
Dermatitis; 2023; 34(2):162-163. PubMed ID: 36917530
[No Abstract] [Full Text] [Related]
6. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
7. A critical evaluation of nemolizumab for prurigo nodularis.
Brooks SG; Yosipovitch G
Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.
Tsoi LC; Hacini-Rachinel F; Fogel P; Rousseau F; Xing X; Patrick MT; Billi AC; Berthier CC; Kahlenberg JM; Lazzari A; Wiegmann H; Ständer S; Piketty C; Julia V; Krishnaswamy JK; Gudjonsson JE
J Allergy Clin Immunol; 2022 Apr; 149(4):1329-1339. PubMed ID: 34857395
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab as promising treatment for prurigo nodularis: current evidences.
Toffoli L; Farinazzo E; Zelin E; Agozzino M; Dianzani C; Di Meo N; Nan K; Zalaudek I; Conforti C
J Dermatolog Treat; 2022 May; 33(3):1306-1311. PubMed ID: 33588666
[TBL] [Abstract][Full Text] [Related]
10. Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab.
Ma F; Gharaee-Kermani M; Tsoi LC; Plazyo O; Chaskar P; Harms P; Patrick MT; Xing X; Hile G; Piketty C; Lazzari A; Van Delm W; Maverakis E; Nakamura M; Modlin RL; Kahlenberg JM; Billi AC; Julia V; Krishnaswamy JK; Gudjonsson JE
J Allergy Clin Immunol; 2024 Jan; 153(1):146-160. PubMed ID: 37506977
[TBL] [Abstract][Full Text] [Related]
11. Nemolizumab: First Approval.
Keam SJ
Drugs; 2022 Jul; 82(10):1143-1150. PubMed ID: 35834124
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.
Ferrucci S; Tavecchio S; Berti E; Angileri L
J Dermatolog Treat; 2021 Jun; 32(4):453-454. PubMed ID: 31442084
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of biologics in prurigo nodularis.
Müller S; Bieber T; Ständer S
Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
[TBL] [Abstract][Full Text] [Related]
14. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
Kabashima K; Matsumura T; Komazaki H; Kawashima M;
N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
[TBL] [Abstract][Full Text] [Related]
16. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.
Pezzolo E; Gambardella A; Guanti M; Bianchelli T; Bertoldi A; Giacchetti A; Donini M; Argenziano G; Naldi L
J Am Acad Dermatol; 2023 Aug; 89(2):430-432. PubMed ID: 37150301
[No Abstract] [Full Text] [Related]
17. Learning from nemolizumab: A promising therapy for prurigo nodularis.
Kim BS
J Allergy Clin Immunol; 2024 Jun; 153(6):1548-1549. PubMed ID: 38460679
[No Abstract] [Full Text] [Related]
18. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
Nilforoushzadeh MA; Heidari N; Ghane Y; Heidari A; Hajikarim-Hamedani A; Hosseini S; Jaffary F; Najar Nobari M; Tavakolzadeh P; Najar Nobari N
Inflammopharmacology; 2024 Apr; 32(2):991-1003. PubMed ID: 38332383
[TBL] [Abstract][Full Text] [Related]
19. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulating Agents as Antipruritics.
Erickson S; Nahmias Z; Rosman IS; Kim BS
Dermatol Clin; 2018 Jul; 36(3):325-334. PubMed ID: 29929604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
